I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

Akero Therapeutics also reported preliminary topline results from its Phase 2b SYMMETRY study, which showed a statistically significant reversal in fibrosis for patients treated with EFX.

Akero Therapeutics, Inc. (NASDAQ: AKRO) President and CEO Andrew Cheng recently sold shares in the company, yielding a total of $178,728. The transaction, which took place on June 11, involved the ...

The positions in the table below reflect the Akero Therapeutics's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position links to the ...

In a recent SEC filing, Rolph Timothy, Chief Scientific Officer of Akero Therapeutics, Inc. (NASDAQ: AKRO), disclosed the sale of company shares valued at approximately $1.74 million. The transactions ...

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics Inc . (NASDAQ: AKRO), recently executed a notable share sale, as per the latest SEC filing. The timing is particularly interesting as ...

Article ‘Count’ and ‘Share’ for Akero Therapeutics based on listed parameters only. The articles listed below published by authors from Akero Therapeutics, organized by journal and article ...